Prof. dr. Patrick Neven, UZ Leuven

🎤 Presentatie: ER+: SERDs, PIK3Kinhibitors
Anti-estrogens with or without CDK 4/6i save lives and delays breast cancer death in all stages of ER+ breast cancer.

However, resistance happens and some resistance mechanisms can be tackled; as such, we have new anti-estrogen therapy options targeting the ER.

We will discuss recent relevant clinical trials targeting the estrogen receptor to optimize endocrine therapy sequences.

We discuss the potential place of endocrine-based schedules including oral SERDs and options beyond CDK 4/6i in early and late stage breast cancer.

💬 Biografie
Patrick Neven is currently Professor at the department of Gynaecological Oncology at the University Hospitals, Leuven, Belgium. He is involved in breast cancer care and a staff member of the Multidisciplinary Breast Centre in Leuven University Hospitals.

Professor Neven graduated in medicine at Leuven Medical School in 1986. He then specialized in Obstetrics and Gynaecology (1991) followed by additional training in gynaecological oncology in London, UK. In 1992 and 1993 he worked as a Clinical Research Fellow at the Royal Marsden and St Bartholomew’s Hospital in London, UK. He became Full Professor at the University Hospitals of Leuven in 2001 following 8 years in private practice at St. John’s Hospital, Brussels, Belgium.

Professor Neven’s research interests include several fields of breast oncology, in particular endocrine therapy and quality of life issues. He has been and is currently the Principal Investigator in several clinical trials on endocrine therapy. He has published over 300 original papers in peer-reviewed journals, more than 300 abstracts and has given numerous lectures at national and international meetings. Professor Neven is involved in many scientific societies and is also a reviewer for many peer-reviewed journals. He has mentored many assistant-doctors, fellows and doctoral students with particular interest in breast cancer care during their training. He is also consulted by several pharmaceutical companies. He is president of the Belgian Society of Senology (BSS). He is a member of the Flemish Association for Obstetrics and Gynaecology (and working group BIG seno), and he is part of many other working groups.